Another randomized open-label phase II/III clinical trial is ongoing (NCT 04396860) in which nivolumab and ipilimumab (anti-CTLA4) are associated with RT vs standard chemoradiotherapy with temozolomide as control arm, in newly diagnosed MGMT unmethylated GBM patients. Here, CTLA4 is linked to glioblastoma.